AQR Capital Management LLC Grows Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

AQR Capital Management LLC grew its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,860 shares of the company’s stock after acquiring an additional 328 shares during the quarter. AQR Capital Management LLC’s holdings in Vaxcyte were worth $820,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PCVX. Goldman Sachs Group Inc. boosted its stake in Vaxcyte by 12.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock worth $30,214,000 after purchasing an additional 52,005 shares during the last quarter. Vanguard Group Inc. raised its holdings in Vaxcyte by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after acquiring an additional 168,125 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Vaxcyte by 25.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock worth $439,000 after purchasing an additional 1,411 shares during the last quarter. Banque Cantonale Vaudoise grew its position in shares of Vaxcyte by 96.7% in the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock valued at $81,000 after purchasing an additional 582 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Vaxcyte by 109.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company’s stock valued at $3,237,000 after purchasing an additional 24,785 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $114.42 on Friday. The company has a market cap of $12.77 billion, a price-to-earnings ratio of -24.45 and a beta of 0.99. The stock’s 50-day moving average is $98.39 and its two-hundred day moving average is $80.91. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter last year, the company posted ($0.70) EPS. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares in the company, valued at $10,479,005.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the completion of the transaction, the senior vice president now directly owns 28,623 shares in the company, valued at $3,127,635.21. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,098 shares of company stock valued at $7,429,653 in the last ninety days. Insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

PCVX has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Leerink Partners lifted their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Bank of America raised their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. BTIG Research increased their price objective on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC upped their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.